Glenmede Trust’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $135K | Sell |
16,208
-26
| -0.2% | -$269 | ﹤0.01% | 1363 |
|
|
2025
Q4 | $201K | Buy |
+16,234
| New | +$174K | ﹤0.01% | 1283 |
|
|
2025
Q1 | $59.6K | Buy |
+12,268
| New | +$102K | ﹤0.01% | 1305 |
|
|
2021
Q2 | – | Sell |
-2,258
| Closed | -$209K | – | 1280 |
|
|
2021
Q1 | $209K | Sell |
2,258
-4,426
| -66% | -$453K | ﹤0.01% | 1057 |
|
|
2020
Q4 | $598K | Buy |
6,684
+639
| +11% | +$58.6K | ﹤0.01% | 805 |
|
|
2020
Q3 | $624K | Sell |
6,045
-722
| -11% | -$77.8K | ﹤0.01% | 723 |
|
|
2020
Q2 | $535K | Sell |
6,767
-127
| -2% | -$9.46K | ﹤0.01% | 748 |
|
|
2020
Q1 | $371K | Hold |
6,894
| – | – | ﹤0.01% | 992 |
|
|
2019
Q4 | $371K | Sell |
6,894
-508
| -7% | -$27.6K | ﹤0.01% | 992 |
|
|
2019
Q3 | $386 | Buy |
7,402
+56
| +0.8% | +$2.61K | ﹤0.01% | 967 |
|
|
2019
Q2 | $354 | Sell |
7,346
-606,923
| -99% | -$29.1M | ﹤0.01% | 998 |
|
|
2019
Q1 | $31K | Buy |
614,269
+98,264
| +19% | +$5.8M | 0.14% | 226 |
|
|
2018
Q4 | $30.6K | Sell |
516,005
-281,403
| -35% | -$18.1M | 0.15% | 205 |
|
|
2018
Q3 | $52.5M | Sell |
797,408
-134,549
| -14% | -$7.85M | 0.21% | 135 |
|
|
2018
Q2 | $47.1M | Sell |
931,957
-51,473
| -5% | -$2.68M | 0.21% | 150 |
|
|
2018
Q1 | $45.7M | Hold |
983,430
| – | – | 0.19% | 159 |
|
|
2017
Q4 | $45.7M | Sell |
983,430
-528,961
| -35% | -$22.3M | 0.19% | 159 |
|
|
2017
Q3 | $61.2M | Sell |
1,512,391
-212,989
| -12% | -$7.71M | 0.27% | 94 |
|
|
2017
Q2 | $50M | Hold |
1,725,380
| – | – | 0.24% | 116 |
|
|
2017
Q1 | $50M | Buy |
1,725,380
+254,633
| +17% | +$7.75M | 0.24% | 116 |
|
|
2016
Q4 | $48.3M | Buy |
1,470,747
+168,260
| +13% | +$5.04M | 0.26% | 103 |
|
|
2016
Q3 | $41.1M | Buy |
1,302,487
+347,808
| +36% | +$10.1M | 0.23% | 118 |
|
|
2016
Q2 | $26.8M | Buy |
954,679
+206,122
| +28% | +$8.08M | 0.16% | 219 |
|
|
2016
Q1 | $27.2M | Sell |
748,557
-40,531
| -5% | -$1.43M | 0.18% | 195 |
|
|
2015
Q4 | $31.6M | Sell |
789,088
-86,639
| -10% | -$3.02M | 0.22% | 134 |
|
|
2015
Q3 | $24.9M | Buy |
875,727
+161,902
| +23% | +$5.33M | 0.18% | 175 |
|
|
2015
Q2 | $23.5M | Sell |
713,825
-4,850
| -0.7% | -$150K | 0.17% | 204 |
|
|
2015
Q1 | $20.7M | Buy |
718,675
+6,046
| +0.8% | +$173K | 0.15% | 223 |
|
|
2014
Q4 | $19.4M | Buy |
712,629
+48,034
| +7% | +$1.14M | 0.15% | 216 |
|
|
2014
Q3 | $14.2M | Buy |
664,595
+84,023
| +14% | +$1.92M | 0.12% | 245 |
|
|
2014
Q2 | $13M | Buy |
580,572
+165,649
| +40% | +$3.86M | 0.12% | 254 |
|
|
2014
Q1 | $10.5M | Buy |
+414,923
| New | +$10.5M | 0.1% | 281 |
|
Other funds holding EBS
VCM
PCM
VPM
Glenmede Trust's EBS Position: Q1 2026 in Review
Glenmede Trust reduced its Emergent Biosolutions (EBS) stake by 0.16% in Q1 2026, selling an estimated $269 and leaving 16,208 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #1363.
Glenmede Trust first reported a position in EBS in Q1 2014 and has held it in 32 quarters since. The position peaked at $61.2M in Q3 2017. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.
- Glenmede Trust held 16,208 shares of Emergent Biosolutions worth $135K as of Q1 2026.
- Glenmede Trust sold 26 Emergent Biosolutions shares in Q1 2026, an estimated $269.
- Emergent Biosolutions made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #1363 holding.
- Glenmede Trust first reported a position in Emergent Biosolutions in Q1 2014 and has held it in 32 quarters since.
- Glenmede Trust's Emergent Biosolutions position peaked at $61.2M in Q3 2017.
- 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.
Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.